The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission: Systematic Review and Meta-analysis of Prospective Clinical Trials
Open accessAbstract
CONTEXT: The optimal treatment of acute myeloid leukemia (AML) in first complete remission (CR1) is uncertain. Current consensus, based on cytogenetic risk, recommends myeloablative allogeneic stem cell transplantation (SCT) for poor-risk but not for good-risk AML. Allogeneic SCT, autologous transplantation, and consolidation chemotherapy are considered of equivalent benefit for intermediate-risk AML. OBJECTIVE: To quantify relapse-free survival (RFS) and overall survival benefit of allogeneic SCT for AML in CR1 overall and also for good-, intermediate-, and poor-risk AML. METHODS: Systematic review and meta-analysis of prospective trials evaluating allogeneic SCT vs nonallogeneic SCT therapies for AML in CR1. The search used the combined search terms allogeneic; acut* and leukem*/leukaem*/leucem*/leucaem*/aml; myelo* or nonlympho* in the PubMed, Embase, and Cochrane Registry of Controlled Trials databases in March 2009. The search identified 1712 articles. STUDY SELECTION: Prospective trials assigning adult patients with AML in CR1 to undergo allogeneic SCT vs nonallogeneic SCT treatment(s) based on donor availability and trials reporting RFS and/or overall survival outcomes on an intention-to-treat, donor vs no-donor basis were identified. DATA EXTRACTION: Two reviewers independently extracted study characteristics, interventions, and outcomes. Hazard ratios (HRs) with 95% confidence intervals (CIs) were determined. DATA SYNTHESIS: Overall, 24 trials and 6007 patients were analyzed (5951 patients in RFS analyses and 5606 patients in overall survival analyses); 3638 patients were analyzed by cytogenetic risk (547, 2499, and 592 with good-, intermediate-, and poor-risk AML, respectively). Interstudy heterogeneity was not significant. Fixed-effects meta-analysis was performed. Compared with nonallogeneic SCT, the HR of relapse or death with allogeneic SCT for AML in CR1 was 0.80 (95% CI, 0.74-0.86). Significant RFS benefit of allogeneic SCT was documented for poor-risk (HR, 0.69; 95% CI, 0.57-0.84) and intermediate-risk AML (HR, 0.76; 95% CI, 0.68-0.85) but not for good-risk AML (HR, 1.06; 95% CI, 0.80-1.42). The HR of death with allogeneic SCT for AML in CR1 was 0.90 (95% CI, 0.82-0.97). Significant overall survival benefit with allogeneic SCT was documented for poor-risk (HR, 0.73; 95% CI, 0.59-0.90) and intermediate-risk AML (HR, 0.83; 95% CI, 0.74-0.93) but not for good-risk AML (HR, 1.07; 95% CI, 0.83-1.38). CONCLUSION: Compared with nonallogeneic SCT therapies, allogeneic SCT has significant RFS and overall survival benefit for intermediate- and poor-risk AML but not for good-risk AML in first complete remission.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
Meta-analysis of Observational Studies in Epidemiology<SUBTITLE>A Proposal for Reporting</SUBTITLE>
Stroup, D. F. (2000) · JAMA · doi:10.1001/jama.283.15.2008 · Cited by 20,623
Operating characteristics of a rank correlation test for publication bias
Begg, C. B., & Mazumdar, M. (1994) · Biometrics · doi:10.2307/2533446 · Cited by 16,955
The combination of estimates from different experiments
Cochran, W. G. (1954) · Biometrics · doi:10.2307/3001666 · Cited by 5,380
Moher, D., Cook, D. J., Eastwood, S., Olkin, I., Rennie, D., & Stroup, D. F. (1999) · The Lancet · doi:10.1016/s0140-6736(99)04149-5 · Cited by 4,826
Parmar, M. K. B., Torri, V., & Stewart, L. (1998) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8 · Cited by 4,802
Sorror, M. L., Maris, M. B., Storb, R., Baron, F., Sandmaier, B. M., Maloney, D. G., & Storer, B. (2005) · Blood · doi:10.1182/blood-2005-05-2004 · Cited by 2,969
The Hazards of Scoring the Quality of Clinical Trials for Meta-analysis
Jüni, P. (1999) · JAMA · doi:10.1001/jama.282.11.1054 · Cited by 1,981 · cited 6×
“Hewlett et al,13 1995 S8125 1982-1986 28 (16-49) 32 (13-39)b 111 (83-142) No No NR NR”
InfluentialMutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia
Schlenk, R. F., Döhner, K., Krauter, J., Fröhling, S., Corbacioglu, A., Bullinger, L., Habdank, M., Späth, D., Morgan, M., Benner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074306 · Cited by 1,628
Self-citationSlovak, M. L., Kopecky, K. J., Cassileth, P. A., Harrington, D. H., Theil, K. S., Mohamed, A., Paietta, E., Willman, C. L., Head, D. R., Rowe, J. M., et al. (2000) · Blood · doi:10.1182/blood.v96.13.4075 · Cited by 1,601
Self-citationEstey, E., & Döhner, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69780-8 · Cited by 1,296
Self-citationInvited commentary: a critical look at some popular meta-analytic methods
Greenland, S. (1994) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a117248 · Cited by 511
Cornelissen, J. J., van Putten, W. L. J., Verdonck, L. F., Theobald, M., Jacky, E., Daenen, S. M. G., van Marwijk Kooy, M., Wijermans, P., Schouten, H., Huijgens, P. C., et al. (2007) · Blood · doi:10.1182/blood-2006-06-025627 · Cited by 471
MicroRNA Expression in Cytogenetically Normal Acute Myeloid Leukemia
Marcucci, G., Radmacher, M. D., Maharry, K., Mrózek, K., Ruppert, A. S., Paschka, P., Vukosavljevic, T., Whitman, S. P., Baldus, C. D., Langer, C., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074256 · Cited by 441
Suciu, S. (2003) · Blood · doi:10.1182/blood-2002-12-3714 · Cited by 347
Sorror, M. L., Giralt, S., Sandmaier, B. M., De Lima, M., Shahjahan, M., Maloney, D. G., Deeg, H. J., Appelbaum, F. R., Storer, B., & Storb, R. (2007) · Blood · doi:10.1182/blood-2007-06-096966 · Cited by 326
Self-citationHarousseau, J., Cahn, J.-Y. Y., Pignon, B., Witz, F., Milpied, N. J., Delain, M., Lioure, B., Lamy, T., Desablens, B., Guilhot, F., et al. (1997) · PubMed · doi:10.1182/blood.v90.8.2978 · Cited by 313
Synthesis of Environmental Evidence: Nitrogen Dioxide Epidemiology Studies
Hasselblad, V., Eddy, D. M., & Kotchmar, D. J. (1992) · Journal of the Air & Waste Management Association · doi:10.1080/10473289.1992.10467018 · Cited by 202
Delaunay, J. (2003) · Blood · doi:10.1182/blood-2002-11-3527 · Cited by 198
Molecular characterization of acute myeloid leukemia
Dohner, K., & Dohner, H. (2008) · Haematologica · doi:10.3324/haematol.13345 · Cited by 167
Oliansky, D. M., Appelbaum, F., Cassileth, P. A., Keating, A., Kerr, J., Nieto, Y., Stewart, S., Stone, R. M., Tallman, M. S., McCarthy, P. L., et al. (2008) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2007.11.002 · Cited by 158
Self-citationHow to avoid bias when comparing bone marrow transplantation with chemotherapy.
Gray, R. G., & Wheatley, K. (1991) · PubMed · Cited by 156
Schlenk, R. F., Benner, A., Hartmann, F., del Valle, F., Weber, C., Pralle, H., Fischer, J. T., Gunzer, U., Pezzutto, A., Weber, W. P., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2403009 · Cited by 119
Self-citationInvited Commentary: Re: “A Critical Look at Some Popular Meta-Analytic Methods”
Olkin, I. (1994) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a117249 · Cited by 115
Keating, S., de Witte, T., Suciu, S., Willemze, R., Hayat, M., Labar, B., RESEGOTTI, L., Ferrini, P. R., Caronia, F. P., Dardenne, M., et al. (1998) · British Journal of Haematology · doi:10.1111/j.1365-2141.1998.896hm3674.x · Cited by 92
Nathan, P. C., Sung, L., Crump, M., & Beyene, J. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh003 · Cited by 82
Schiller, G. J., Nimer, S. D., Territo, M., et al. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.1.41 · Cited by 75
Breems, D. A., Boogaerts, M., Dekker, A. W., van Putten, W. L. J., Sonneveld, P., Huijgens, P. C., der Lelie, J. V., Vellenga, E., Gratwohl, A. A., Verhoef, G. E. G., et al. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05282.x · Cited by 73
Levi, I., Grotto, I., Yerushalmi, R., Ben‐Bassat, I., & Shpilberg, O. (2004) · Leukemia Research · doi:10.1016/j.leukres.2003.10.029 · Cited by 55
Hematopoietic Stem Cell Transplantation in Adults with Acute Myeloid Leukemia
Hamadani, M., Awan, F. T., & Copelan, E. A. (2008) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2008.02.019 · Cited by 38
Cited by
Döhner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Büchner, T., Burnett, A. K., Dombret, H., Fenaux, P., Grimwade, D., Larson, R. A., et al. (2010) · Blood · doi:10.1182/blood-2009-07-235358 · Cited by 3,373
Self-citationDöhner, H., Weisdorf, D. J., & Bloomfield, C. D. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1406184 · Cited by 3,306
Self-citation‘Acute myeloid leukemia: a comprehensive review and 2016 update’
De Kouchkovsky, I., & Abdul-Hay, M. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2016.50 · Cited by 1,317
Therapeutic Advances in Acute Myeloid Leukemia
Burnett, A., Wetzler, M., & Löwenberg, B. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.1820 · Cited by 787
Short, N. J., Rytting, M. E., & Cortes, J. E. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31041-9 · Cited by 781
Metadata
- Authors
- Koreth, J., Schlenk, R., Kopecky, K. J., Honda, S., Sierra, J., Djulbegovic, B. J., Wadleigh, M., DeAngelo, D. J., Stone, R. M., Sakamaki, H., Appelbaum, F. R., Döhner, H., Antin, J. H., Soiffer, R. J., & Cutler, C.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2009-06-10
- Volume
- 301
- Issue
- 22
- Pages
- 2349
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2074425311
- Cited by
- 886
- References
- 32
- FWCI
- 37.24
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.